The Second Canadian Symposium on Hepatitis C Virus: A Call to Action
In Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of those who undergo treatment will be approved. G...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2013/242405 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560439945330688 |
|---|---|
| author | Jason Grebely Marc Bilodeau Jordan J Feld Julie Bruneau Benedikt Fischer Jennifer F Raven Eve Roberts Norma Choucha Rob P Myers Selena M Sagan Joyce A Wilson Frank Bialystok D Lorne Tyrrell Michael Houghton Mel Krajden on behalf of the National CIHR Research Training Program in Hepatitis C |
| author_facet | Jason Grebely Marc Bilodeau Jordan J Feld Julie Bruneau Benedikt Fischer Jennifer F Raven Eve Roberts Norma Choucha Rob P Myers Selena M Sagan Joyce A Wilson Frank Bialystok D Lorne Tyrrell Michael Houghton Mel Krajden on behalf of the National CIHR Research Training Program in Hepatitis C |
| author_sort | Jason Grebely |
| collection | DOAJ |
| description | In Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of those who undergo treatment will be approved. Given that most of those already infected are aging and at risk for progressive liver disease, building research-based interdisciplinary prevention, care and treatment capacity is an urgent priority. In an effort to increase the dissemination of knowledge in Canada in this rapidly advancing field, the National CIHR Research Training Program in Hepatitis C (NCRTP-HepC) established an annual interdisciplinary Canadian Symposium on Hepatitis C Virus. The first symposium was held in Montreal, Quebec, in 2012, and the second symposium was held in Victoria, British Columbia, in 2013. The current article presents highlights from the 2013 meeting. It summarizes recent advances in HCV research in Canada and internationally, and presents the consensus of the meeting participants that Canada would benefit from having its own national HCV strategy to identify critical gaps in policies and programs to more effectively address the challenges of expanding HCV screening and treatment. |
| format | Article |
| id | doaj-art-57253eb307e94ad1b36afc858508d059 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-57253eb307e94ad1b36afc858508d0592025-02-03T01:27:34ZengWileyCanadian Journal of Gastroenterology0835-79002013-01-01271162763210.1155/2013/242405The Second Canadian Symposium on Hepatitis C Virus: A Call to ActionJason Grebely0Marc Bilodeau1Jordan J Feld2Julie Bruneau3Benedikt Fischer4Jennifer F Raven5Eve Roberts6Norma Choucha7Rob P Myers8Selena M Sagan9Joyce A Wilson10Frank Bialystok11D Lorne Tyrrell12Michael Houghton13Mel Krajden14on behalf of the National CIHR Research Training Program in Hepatitis CThe Kirby Institute, The University of New South Wales, Sydney, New South Wales, AustraliaLiver Unit, Department of Medicine, Université de Montréal, Montréal, Québec, CanadaToronto Centre for Liver Disease, University of Toronto, Toronto, CanadaCRCHUM, Université de Montréal, Montréal, Québec, CanadaSimon Fraser University, Vancouver, British Columbia, CanadaCanadian Institutes of Health Research – Institute of Infection and Immunity, Laurier, Québec, CanadaUniversity of Toronto, Toronto, Ontario, CanadaLiver Unit, Department of Medicine, Université de Montréal, Montréal, Québec, CanadaLiver Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, CanadaDepartment of Microbiology & Immunology, McGill University, Montreal, Quebec, CanadaDepartment of Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, CanadaUniversity of Toronto, Toronto, Ontario, CanadaLi Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, CanadaLi Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, CanadaBritish Columbia Centre for Disease Control, Vancouver, British Columbia, CanadaIn Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of those who undergo treatment will be approved. Given that most of those already infected are aging and at risk for progressive liver disease, building research-based interdisciplinary prevention, care and treatment capacity is an urgent priority. In an effort to increase the dissemination of knowledge in Canada in this rapidly advancing field, the National CIHR Research Training Program in Hepatitis C (NCRTP-HepC) established an annual interdisciplinary Canadian Symposium on Hepatitis C Virus. The first symposium was held in Montreal, Quebec, in 2012, and the second symposium was held in Victoria, British Columbia, in 2013. The current article presents highlights from the 2013 meeting. It summarizes recent advances in HCV research in Canada and internationally, and presents the consensus of the meeting participants that Canada would benefit from having its own national HCV strategy to identify critical gaps in policies and programs to more effectively address the challenges of expanding HCV screening and treatment.http://dx.doi.org/10.1155/2013/242405 |
| spellingShingle | Jason Grebely Marc Bilodeau Jordan J Feld Julie Bruneau Benedikt Fischer Jennifer F Raven Eve Roberts Norma Choucha Rob P Myers Selena M Sagan Joyce A Wilson Frank Bialystok D Lorne Tyrrell Michael Houghton Mel Krajden on behalf of the National CIHR Research Training Program in Hepatitis C The Second Canadian Symposium on Hepatitis C Virus: A Call to Action Canadian Journal of Gastroenterology |
| title | The Second Canadian Symposium on Hepatitis C Virus: A Call to Action |
| title_full | The Second Canadian Symposium on Hepatitis C Virus: A Call to Action |
| title_fullStr | The Second Canadian Symposium on Hepatitis C Virus: A Call to Action |
| title_full_unstemmed | The Second Canadian Symposium on Hepatitis C Virus: A Call to Action |
| title_short | The Second Canadian Symposium on Hepatitis C Virus: A Call to Action |
| title_sort | second canadian symposium on hepatitis c virus a call to action |
| url | http://dx.doi.org/10.1155/2013/242405 |
| work_keys_str_mv | AT jasongrebely thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT marcbilodeau thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT jordanjfeld thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT juliebruneau thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT benediktfischer thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT jenniferfraven thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT everoberts thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT normachoucha thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT robpmyers thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT selenamsagan thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT joyceawilson thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT frankbialystok thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT dlornetyrrell thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT michaelhoughton thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT melkrajden thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT onbehalfofthenationalcihrresearchtrainingprograminhepatitisc thesecondcanadiansymposiumonhepatitiscvirusacalltoaction AT jasongrebely secondcanadiansymposiumonhepatitiscvirusacalltoaction AT marcbilodeau secondcanadiansymposiumonhepatitiscvirusacalltoaction AT jordanjfeld secondcanadiansymposiumonhepatitiscvirusacalltoaction AT juliebruneau secondcanadiansymposiumonhepatitiscvirusacalltoaction AT benediktfischer secondcanadiansymposiumonhepatitiscvirusacalltoaction AT jenniferfraven secondcanadiansymposiumonhepatitiscvirusacalltoaction AT everoberts secondcanadiansymposiumonhepatitiscvirusacalltoaction AT normachoucha secondcanadiansymposiumonhepatitiscvirusacalltoaction AT robpmyers secondcanadiansymposiumonhepatitiscvirusacalltoaction AT selenamsagan secondcanadiansymposiumonhepatitiscvirusacalltoaction AT joyceawilson secondcanadiansymposiumonhepatitiscvirusacalltoaction AT frankbialystok secondcanadiansymposiumonhepatitiscvirusacalltoaction AT dlornetyrrell secondcanadiansymposiumonhepatitiscvirusacalltoaction AT michaelhoughton secondcanadiansymposiumonhepatitiscvirusacalltoaction AT melkrajden secondcanadiansymposiumonhepatitiscvirusacalltoaction AT onbehalfofthenationalcihrresearchtrainingprograminhepatitisc secondcanadiansymposiumonhepatitiscvirusacalltoaction |